# Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

> **NCT00089245** · PHASE1 · TERMINATED · sponsor: **Y-mAbs Therapeutics** · enrollment: 177 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Neuroblastoma
- Sarcoma

## Interventions

- **DRUG:** Iodine I 131 MOAB 8H9
- **DRUG:** Iodine I 131 MOAB 8H9

## Key facts

- **NCT ID:** NCT00089245
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02-05
- **Primary completion:** 2022-02-02
- **Final completion:** 2022-02-02
- **Target enrollment:** 177 (ACTUAL)
- **Why stopped:** Corporate business decision. No safety or efficacy concerns.
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089245, "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00089245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*